Journal of Cytology & Histology

Ross C

Publications

• Research Article
  Comparison of Clinic-Pathological, Molecular Features and PD-L1 Status in a Series of Non-small Cell Lung Cancers: Are Real Life Data Similar to Clinical Trials results?
  Author(s): Elshiekh M, Mani A, Kitson R, Josephides E, Clifford A, Rieu R, Desai S, Gupta N, Berry M, Bloch S, Ross C, Anderson J, Nandi J, Roddie M, Copley S, Denton A, Hatcher O, Power D, Lewanski C, Newsom-Davis T and Patrizia ViolaElshiekh M, Mani A, Kitson R, Josephides E, Clifford A, Rieu R, Desai S, Gupta N, Berry M, Bloch S, Ross C, Anderson J, Nandi J, Roddie M, Copley S, Denton A, Hatcher O, Power D, Lewanski C, Newsom-Davis T and Patrizia Viola
  
  Objective: Immunotherapy is a promising treatment option for a subset of lung cancers as it utilizes the host’s own immune system to attack tumors cells. Selection of patients who are likely to respond to immunotherapy is based on PD-L1 expression, a specific biomarker. Clinic-pathological correlation of PD-L1 status and NSCLC has been explored in several studies and large clinical trials. However, there is discrepancy of data as several antibodies are available. We looked at a series of lung tumors to study the association between PD-L1 expression and patient characteristics in our daily setting to improve the selection of patients more likely to express this marker. Results were compared to those available in literature using the same antibody.Methods: We analysed PD-L1 status (using Dako clone 22C3) in 170 non-s.. Read More»
  

  Abstract PDF